Innovent Bio (01801.HK) and Sanigen Biotechnology jointly announced the completion of the first-in-human phase I clinical trial of IBI3016, a targeted silencing RNA drug for angiotensinogen (AGT). The first subject has been dosed.
The drug is mainly used to treat hypertension. In December 2023, Innovent Bio and Sanigen Biotechnology reached a strategic cooperation to jointly promote the development of IBI3016. At the same time, Innovent Bio obtained the exclusive rights to future development, production, and commercialization of the drug in different regions.